胸腺基质淋巴细胞生成素在哮喘发病机制和治疗中的研究进展

Research Progress of Thymic Stromal Lymphopoietin in Pathogenesis and Treatment of Asthma

支气管哮喘是一种以反复发作性喘息、气急、胸闷、咳嗽为临床表现的气道慢性炎症疾病。胸腺基质淋巴细胞生成素(TSLP)作为一种与过敏性疾病、癌症等相关的细胞因子,近年在支气管哮喘相关研究中受到广泛关注。TSLP介导的辅助性T细胞2型炎症反应可通过某些信号途径参与支气管哮喘的发生发展。随着研究的深入发现,不同TSLP亚型的作用不同,且TSLP参与哮喘的过程涉及多种激活途径。以TSLP为靶点的生物制剂开发出多种有效形式,如抗TSLP单抗与双抗,有望成为治疗哮喘的重要药物靶标。

Bronchial asthma is a chronic airway inflammatory disease characterized by recurrent wheezing,shortness of breath,chest tightness and cough.Thymic stromal lymphopoietin(TSLP),as a cytokine related to allergic diseases and cancer,has been widely concerned in bronchial asthma related research in recent years.TSLP mediated helper T cell type 2 inflammatory response can participate in the occurrence and development of bronchial asthma through some signal pathways.With the deepening of the study of TSLP,it is found that different TSLP subtypes have different effects,which means that TSLP involves a variety of activation pathways in the process of asthma.Biological agents targeting TSLP have developed a variety of effective forms,such as anti-TSLP monoclonal antibody and double antibody,which is expected to become an important drug target for the treatment of asthma.